An interventional study of Endourage 1200 mg OMD ™ Oral Mucosal Drops and Isolate in Alcohol Drinking, Alcohol Use, Unspecified and Alcohol Abstinence, sponsored by Endourage, LLC. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-07.
Sponsored by Endourage, LLC · Not applicable, Interventional, and Supportive care
This is the first clinical trial of Endourage OMD 1200 for persons desiring to reduce their alcohol consumption.
CBD is the second most abundant component of the cannabis plant after tetrahydrocannabinol (THC). Unlike THC, CBD does not get users high, but there is some evidence suggesting that it might have anti-anxiety, anticonvulsant, anti-inflammatory and immune boosting, antioxidant effects.
Currently, the only CBD product approved by the Food and Drug Administration is a prescription oil called Epidiolex (Greenwich Biosciences, Inc. 2018). It is approved to treat two types of epilepsy. Aside from Epidiolex, state laws on the use of CBD vary. While CBD is being studied as a treatment for a wide range of conditions, including Parkinson's disease, schizophrenia, diabetes, multiple sclerosis and anxiety, and addiction, research supporting the drug's benefits is still limited.
CBD use carries some risks. Though it is often well-tolerated, CBD can cause side effects, such as dry mouth, diarrhea, reduced appetite, drowsiness, and fatigue. CBD can also interact with other medications you are taking, such as blood thinners.
Another cause for concern is the unreliability of the purity and dosage of CBD in products. A recent study of 84 CBD products bought online showed that more than a quarter of the products contained less CBD than labeled. In addition, THC was found in 18 products. If you plan to use products containing CBD, talk to your primary health care provider.
People take cannabidiol by mouth for anxiety, bipolar disorder, a muscle disorder called dystonia, seizures, multiple sclerosis, Parkinson's disease, and schizophrenia.
Cannabidiol is possibly safe when taken by mouth and appropriately in adults. Cannabidiol doses of up to 300 mg daily have been used safely for up to 6 months. Higher doses of 1200-1500 mg daily have been used safely for up to 4 weeks. Cannabidiol sprays used under the tongue have been used in doses of 2.5 mg for up to 2 weeks.
925 studies on the registry are indexed under Alcohol Drinking; 172 are open to participants now.
Browse Alcohol Drinking studies →Endourage, LLC is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Placebo Isolate Placebo (Hemp seed oil and peppermint flavoring)
Dietary Supplement: Isolate · Other: Placebo · Dietary Supplement: Peppermint Oil, masking flavor
Isolate Placebo Isolate (CBD no terpenes Hemp seed oil \[slightly lower concentration of CBD ratio\])
Dietary Supplement: Isolate · Other: Placebo · Dietary Supplement: Peppermint Oil, masking flavor
Placebo OMD Endourage OMD (Full flower extract with a 1:1 ratio of cannabis terpenes, Hemp seed oil and peppermint flavoring)
Dietary Supplement: Endourage 1200 mg OMD ™ Oral Mucosal Drops · Other: Placebo · Dietary Supplement: Peppermint Oil, masking flavor
OMD Placebo Endourage OMD (Full flower extract with a 1:1 ratio of cannabis terpenes, Hemp seed oil and peppermint flavoring)
Dietary Supplement: Endourage 1200 mg OMD ™ Oral Mucosal Drops · Other: Placebo · Dietary Supplement: Peppermint Oil, masking flavor
The CBD/THC ratio of OMD 1200 is 14:1 and the CBD/Terpene ratio is 1:1. Each ¼ dropper contains 10.2 mg of CBD and 0.7 mg of THC. The total % THC is 0.28%. These ratios indicate that the product will not cause euphoria.
Also known as: OMD-1200, OMD 1200, Endourage OMD 1200
The isolate formulation contains 0% cannabinoids (CBD 0.00%; CBDa 0.00%; detla 9 THC 0.00%; THCa 0.00%).
Total CBD = CBD + (CBD-A \* 0.877). Total THC = THCA-A \* 0.877 + Delta 9 THC, ND = \<LOQ, T-Caryophyllene = Trans-Caryophyllene, \<LOQ = Less Than Limit of Quantitation, QNS = Quantity Not Sufficient. (%) = Percent, (ppm) = Parts per Million, (ppb) = Parts per Billion, (μg/Kg) = Microgram per Kilogram, (mg/g) = Milligram per Gram, ppm = (μg/g), ppb = (μg/kg),
Mentha piperita Leaf /Stem Oil; Physical state: Liquid. Color: Colorless to pale yellow; Characteristic peppermint odor; Not dangerous goods.
Also known as: Peppermint Oil, Peppermint Oil, Natural
Anxiety scores
Generalized Anxiety Disorder (GAD-7), measure for anxiety. Baseline scores will be compared to scores at end of study across arms. Change in anxiety scores from baseline to end of study will be measured. Range from 0-4 for minimal; 5-9 mild; 10-14 moderate; 15-21 severe. Changes will be compared across arms. Increased scores will indicate that study product was not effective in decreasing symptoms measured (anxiety).
Time frame: 112 days (4-months)
Depression scores
Patient Health Questionnaire (PHQ-9), measure for depression. Change in depression scores from baseline to end of study. Total Score for Depression Severity will be compared across arms from baseline to end of study at 112-days. Score ranges from: 1-4 Minimal depression; 5-9 Mild depression; 10-14 Moderate depression; 15-19 Moderately severe depression; 20-27 Severe depression. Increased scores indicate that study product is not effective in decreasing symptoms measured (depression).
Time frame: 112 days (4-months)
Alcohol craving scores
The Alcohol Craving Questionnaire Short Form (ACQ-SF-R) will be compared from baseline to end of study. Changes in craving score will be measured in each arm of study. Scores from 1-7 (strongly disagree to strongly agree) is measured across 12 items and 4 sub-scales (\[1\] compulsivity, \[2\] expectancy, \[3\] purposefulness, and \[4\] emotionality). The sum of the raw scores for each factor will be calculated and compared from baseline to the end of study across arms. Increased scores indicate that study product is not effective in reducing cravings for alcohol.
Time frame: 112 days (4-months)
To determine CBDs impact on anxiety, depression, and alcohol craving that trigger desires to consume alcohol versus abstain.
Daily diary of symptom(s), dose(s) of study product and alcohol use will be kept by participants. Diary entries of symptoms, daily dose of study product and daily alcohol use will be measured and compared across study arms from baseline to end of study.
Time frame: 112 days (4-months)
Plan to share: No — Not applicable/none planned
This study is withdrawn, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.